Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation

The purpose of this study was to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover markers in patients with orthotopic liver transplantation (OLT). In the prospective, controlled, open study with 24 months of follow-up, 98 patients with OLT were randomised to...

Full description

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2006-06, Vol.17 (6), p.942-949
Main Authors: ATAMAZ, F, HEPGULER, S, AKYILDIZ, M, KARASU, Z, KILIC, M
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Adult
Alendronate - therapeutic use
Awards & honors
Biological and medical sciences
Biomarkers - metabolism
Bisphosphonates
Bone and Bones - physiology
Bone density
Bone Density - drug effects
Bone Density Conservation Agents - therapeutic use
Calcitriol - administration & dosage
Calcium - administration & dosage
Creatinine
Diseases of the osteoarticular system
Drug dosages
Female
Femur - drug effects
Femur - metabolism
Fractures
Humans
Injuries of the limb. Injuries of the spine
Investigative techniques, diagnostic techniques (general aspects)
Liver diseases
Liver Transplantation
Lumbar Vertebrae - drug effects
Lumbar Vertebrae - metabolism
Male
Medical sciences
Metabolism
Middle Aged
Osteoarticular system. Muscles
Osteoporosis
Osteoporosis - prevention & control
Osteoporosis. Osteomalacia. Paget disease
Parathyroid Hormone - metabolism
Prospective Studies
Radiodiagnosis. Nmr imagery. Nmr spectrometry
Transplants & implants
Traumas. Diseases due to physical agents
Vitamin deficiency
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate the effects of alendronate (ALN) on bone mineral density (BMD) and bone turnover markers in patients with orthotopic liver transplantation (OLT). In the prospective, controlled, open study with 24 months of follow-up, 98 patients with OLT were randomised to receive ALN 70 mg weekly or no ALN; calcium (Ca) 1,000 mg daily and 0.5 mcg calcitriol daily were provided to all patients. Lumbar spine (LS) and hip BMDs were measured at 6-month intervals by dual-energy X-ray absorptiometry (DEXA). Spinal radiographs were obtained to assess vertebral fractures. Additionally, bone turnover markers, serum parathyroid hormone (PTH) and biochemical parameters were determined every 3 months. Compared with the control group, the ALN group showed significant increases in BMD of the LS (5.1+/-3.9% vs 0.4+/-4.2%, p
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-006-0082-5